

TNF-Blockers Restore Normal Growth in Children

BY ELIZABETH MEHCATIE
Senior Writer

A study that evaluated children with severe juvenile idiopathic arthritis before and after starting anti-tumor necrosis factor treatment indicated that these biological agents appear to be effective in restoring normal growth in this population, reported Dr. Pirjo Tynjälä.

The results also suggest that the improvements in growth are related to the impact these treatments have on inflammation, wrote Dr. Tynjälä of the Hospital for Children and Adolescents, Helsinki University Central Hospital, and her associates (Ann. Rheum. Dis. 2006;65:1044-9).

The study followed the growth of 71 chil-

dren with polyarticular disease—course juvenile idiopathic arthritis for 2 years before and 2 years after starting etanercept (43 patients) or infliximab (28 patients). When treatment started, mean age was 9.6 years, mean disease duration was 5.7 years, and the children were refractory to conventional disease-modifying antirheumatic drugs. The dose of etanercept (Enbrel) was 0.4 mg/kg twice a week; the dose of infliximab (Remicade) was 80-200 mg every 6-8 weeks administered intravenously.

In the group overall, the mean growth velocity increased significantly during treatment, which was mostly because of the increase in the 53 children whose growth was delayed before starting treatment. Among the 18 children whose growth was normal or accelerated before treatment, growth velocity increased, but not significantly, during treatment. Over the 4 years, there were no significant differences in the total steroid dose among those with delayed growth and those with normal growth.

After 24 months of treatment, disease was inactive in 52% of the patients, and activity had decreased in the remainder, Dr. Tynjälä and her colleagues wrote.

The change in inflammatory activity “remained a significant predictor of the growth velocity, even after glucocorticoids were taken into account,” suggesting that the improved growth velocity may be because of the reduction in inflammation and not “a direct effect of biological agents on growth or on skeletal maturation.” ■

Continued from previous page

gans, longer life expectancy, and more rapid cell division.

Dr. Slovis said that children receive more radiation than do adults when the same dose of radiation is used. Radiation doses are measured with a phantom and set at a fixed midpoint, he said. This measurement is based on 14 slices, but is independent of the thickness of those slices.

Studies of the effects of radiation in the survivors of the atomic bombings of Hiroshima and Nagasaki include data specific to children.

Among the findings noted by Dr. Friedman is an increased incidence of leukemia, breast cancer, colon cancer, thyroid cancer, and lung cancer. These do not occur immediately, but at the times that would be expected for the specific cancer to develop.

Girls are more radiosensitive than boys, he said, and the risk of cancer development varies dramatically with the patient's age at exposure.

Dr. Slovis said some children with hereditary diseases—including ataxia-telangiectasia, basal cell nevus syndrome, Cockayne's syndrome, Down syndrome, Fanconi's anemia, Gardner's syndrome, Nijmegen breakage syndrome, and Usher's syndrome—are extremely sensitive to radiation and should not be exposed at all, if possible.

He also discouraged the use of radiation in children with hereditary syndromes that have been associated with childhood cancers.

Fetuses and premature babies are especially vulnerable, added Dr. Slovis. He hailed the late Dr. Alice Stewart's work for establishing that radiation in utero increases the relative risk of leukemia and other malignancies.

“How much radiation does a 25-week surviving preemie get?” he asked, comparing them to third-trimester fetuses and urging limited testing in infants. “I don't say don't get an indicated CT,” he said. “I say get the indications, and work it through.” Physicians should be sure each test they order is necessary, should use “the least invasive modality that gives a high certainty of success,” and should discuss the case with a pediatric radiologist whenever they are unsure. ■

NOW AVAILABLE

NEW 
OPANA®
(oxymorphone HCl) 

Tablets

OPANA® is indicated for the relief of moderate to severe acute pain where the use of an opioid is appropriate.

NEW 
OPANA® ER
(oxymorphone HCl) 

Extended-release tablets

OPANA® ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid therapy for an extended period of time.

- OPANA® ER is not intended for use as a prn analgesic.
- OPANA® ER is not indicated for pain in the immediate postoperative period (12–24 hours following surgery) for patients not previously taking opioids because of the risk of oversedation and respiratory depression requiring reversal with opioid antagonists.
- OPANA® ER is not indicated for pain in the postoperative period if the pain is mild or not expected to persist for an extended period of time.

Important Safety Information

OPANA® and OPANA® ER are opioid agonists and Schedule II controlled substances with an abuse liability similar to morphine. OPANA® and OPANA® ER can be abused in a manner similar to other opioid agonists, legal or illicit.

OPANA® ER has a boxed warning as follows:

WARNING: OPANA® ER contains oxymorphone, which is a morphine-like opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.

Oxymorphone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing OPANA® ER in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

OPANA® ER is an extended-release oral formulation of oxymorphone indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

OPANA® ER is NOT intended for use as a prn analgesic.

OPANA® ER TABLETS are to be swallowed whole and are not to be broken, chewed, dissolved, or crushed. Taking broken, chewed, dissolved, or crushed OPANA® ER TABLETS leads to rapid release and absorption of a potentially fatal dose of oxymorphone.

Patients must not consume alcoholic beverages, or prescription or nonprescription medications containing alcohol, while on OPANA® ER therapy. The co-ingestion of alcohol with OPANA® ER may result in increased plasma levels and a potentially fatal overdose of oxymorphone.

OPANA® and OPANA® ER are **contraindicated** in patients with a known hypersensitivity to oxymorphone hydrochloride, morphine analogs such as codeine, or any of the other ingredients of OPANA® and OPANA® ER; in patients with moderate or severe hepatic impairment or in any situation where opioids are contraindicated such as: patients with respiratory depression (in the absence of resuscitative equipment or in unmonitored settings), acute or severe bronchial asthma, hypercarbia, and in any patient who has or is suspected of having paralytic ileus. Respiratory depression is the chief hazard of OPANA® and OPANA® ER, particularly in elderly or debilitated patients. OPANA® and OPANA® ER should be administered with extreme caution to patients with conditions accompanied by hypoxia, hypercapnia, or decreased respiratory reserve such as: asthma, chronic obstructive pulmonary disease or cor pulmonale, severe obesity, sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression, or coma.

Patients receiving other opioid analgesics, general anesthetics, phenothiazines or other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) may experience additive effects resulting in respiratory depression, hypotension, profound sedation, or coma. OPANA® and OPANA® ER should be used with caution in elderly and debilitated patients and in patients who are known to be sensitive to CNS depressants, such as those with cardiovascular, pulmonary, renal, or hepatic disease. OPANA® and OPANA® ER should be used with caution in patients with mild hepatic impairment and in patients with moderate to severe renal impairment. These patients should be started cautiously with lower doses of OPANA® or OPANA® ER while carefully monitoring for side effects.

OPANA® ER is not indicated for preemptive analgesia (administration preoperatively for the management of postoperative pain).

The most common adverse drug reactions (≥10%) reported at least once by patients treated with OPANA® in all clinical trials were nausea and pyrexia. The most common adverse drug reactions (≥10%) in all clinical trials for OPANA® ER were nausea, constipation, dizziness (excluding vertigo), vomiting, pruritus, somnolence, headache, increased sweating, and sedation.

Please see accompanying Brief Summaries of full Prescribing Information, including boxed warning on OPANA® ER, on the following pages.